We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

The recent study by Bolland and colleagues published in the Lancet Diabetes Endocrinology (Oct 4, 2018) is an updated meta-analysis that evaluated the effects of vitamin D supplementation on fractures, […]

Osteoporosis Canada’s Quality Standards for Fracture Liaison Services in Canada were developed to support implementation of effective FLS. They provide clear guidance for healthcare professionals and administrators on what an effective FLS […]

This report provides a national overview on diagnosed osteoporosis, related fractures and the osteoporosis care gap among Canadians 40 years and older.  It reports on administrative data from the Canadian […]

  Our Financials YEAR ENDED MARCH 31, 2022 Osteoporosis Canada’s Program Fund, which accounts for revenue and expenses related to education, advocacy and awareness, administration, and fundraising, had a year-end […]

St. Michael’s Hospital celebrates the 20th anniversary of the establishment of FLS St. Michael’s Hospital celebrates the 20th anniversary of the establishment of FLS St. Michael’s Hospital (SMH) in Toronto […]

Dr. Aliya Khan, Dr. Heather Frame, Dr. Claudia Gagnon, Dr. Rowena Ridout, Dr. Lianne Tile and Dr. Sandra Kim Recommendations from Osteoporosis Canada Rapid Response Team Osteoporosis is a chronic […]

Dr. Aliya Khan, Dr. Heather Frame, Dr. Claudia Gagnon, Dr. Rowena Ridout, Dr. Lianne Tile and Dr. Sandra Kim Recommendations from Osteoporosis Canada Rapid Response Team Osteoporosis is a chronic […]